| DANIEL NADEAU, M.D., Tufts School of Medicine, is clinical director of
the Diabetes Endocrine Nutrition Center, and the principal investigator
for several diabetes clinical trials. He is also a medical reporter for
WABI TV in Bangor, Maine. Dr. Nadeau received his M.S. Degree from Tufts
University School of Nutrition. Dr. Nadeau has also been associate medical director for Abbott International, a major pharmaceutical company, where he studied the design and implementation of nutritional supplements. While at Abbott, Dr. Nadeau researched the role of short-chain fructooligosaccharides (FOS) in health and disease. FOS is a naturally occurring carbohydrate that feeds beneficial bacteria in the gastrointestinal tract. By feeding the "good" bacteria, it may help prevent the overgrowth of "bad" bacteria such as pathogenic E.coli. His studies have shown that supplementation with FOS may reduce levels of toxic compounds, implicated as possible catalysts in the development of colon cancer. In one medical study, FOS was shown to significantly reduce 2 enzymes implicated in the formation of cancer. For the past three years, he has received the National Research Service Award sponsored by the U.S. Department of Health and Human Services. In this video, Dr. Nadeau speaks on FOS & Friendly Bacteria in the Control of Colon Cancer. |